Ionis Pharmaceuticals, Inc.
IONS
$37.31
-$0.31-0.82%
| Weiss Ratings | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.22 | |||
| Price History | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -5.47% | |||
| 30-Day Total Return | -11.67% | |||
| 60-Day Total Return | -17.75% | |||
| 90-Day Total Return | -28.54% | |||
| Year to Date Total Return | -29.43% | |||
| 1-Year Total Return | 1.86% | |||
| 2-Year Total Return | -2.81% | |||
| 3-Year Total Return | 1.19% | |||
| 5-Year Total Return | -44.69% | |||
| 52-Week High % Change | -31.47% | |||
| 52-Week Low % Change | 3.87% | |||
| Price | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $54.44 | |||
| 52-Week Low Price | $35.92 | |||
| 52-Week Low Price (Date) | May 18, 2023 | |||
| 52-Week High Price (Date) | Jan 12, 2024 | |||
| Valuation | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.44B | |||
| Enterprise Value | 5.21B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.67 | |||
| Earnings Per Share Growth | 15.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.99 | |||
| Price/Book (Q) | 18.35 | |||
| Enterprise Value/Revenue (TTM) | 6.70 | |||
| Price | $37.31 | |||
| Enterprise Value/EBITDA (TTM) | -14.68 | |||
| Enterprise Value/EBIT | -14.17 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 145.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 760 931 9200 | |||
| Address | 2855 Gazelle Court Carlsbad, CA 92010 | |||
| Website | www.ionispharma.com | |||
| Country | United States | |||
| Year Founded | 1989 | |||
| Profitability | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -47.31% | |||
| Profit Margin | -49.54% | |||
| Management Effectiveness | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -8.13% | |||
| Return on Equity | -- | |||
| Income Statement | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 776.62M | |||
| Total Revenue (TTM) | 776.62M | |||
| Revenue Per Share | $5.34 | |||
| Gross Profit (TTM) | -147.69M | |||
| EBITDA (TTM) | -354.61M | |||
| EBIT (TTM) | -367.44M | |||
| Net Income (TTM) | -384.77M | |||
| Net Income Avl. to Common (TTM) | -384.77M | |||
| Total Revenue Growth (Q YOY) | -8.45% | |||
| Earnings Growth (Q YOY) | -14.86% | |||
| EPS Diluted (TTM) | -2.67 | |||
| EPS Diluted Growth (Q YOY) | -12.65% | |||
| Balance Sheet | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.21B | |||
| Cash Per Share (Q) | $15.22 | |||
| Total Current Assets (Q) | 2.42B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 296.52M | |||
| Current Ratio (Q) | 7.373 | |||
| Book Value Per Share (Q) | $2.03 | |||
| Total Assets (Q) | 2.76B | |||
| Total Current Liabilities (Q) | 327.65M | |||
| Total Debt (Q) | 1.98B | |||
| Total Liabilities (Q) | 2.47B | |||
| Total Common Equity (Q) | 296.52M | |||
| Cash Flow | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 187.62M | |||
| Cash from Financing (TTM) | 175.57M | |||
| Net Change in Cash (TTM) | 39.86M | |||
| Levered Free Cash Flow (TTM) | -156.69M | |||
| Cash from Operations (TTM) | -323.46M | |||
